Late-phase trial failure for GSK, Prosensa muscular dystrophy drug

09/23/2013 | PharmaTimes (U.K.)

A Phase III trial for drisapersen, a drug by GlaxoSmithKline and Prosensa for treating Duchenne muscular dystrophy, failed to meet primary goals three months after receiving breakthrough therapy designation from the U.S. FDA. The trial among 186 boys suffering from the disease failed to demonstrate significant improvement in walking distance or motor function, compared with a placebo. DMD affects one in 3,500 live male births.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX